{"entity":{"id":"nct06668103","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib","aka":[],"tldr":"A phase 2 trial of ABSK043 in combination with Firmonertinib in non-small-cell lung cancer, run by Abbisko Therapeutics Co, Ltd, now recruiting.","summary":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib is a phase 2 interventional study registered as NCT06668103 by Abbisko Therapeutics Co, Ltd, with 54 participants planned, started 2024-11-25 and due to reach its primary completion in 2027-12-30. Interventions recorded: ABSK043 in combination with Firmonertinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06668103","url":"https://clinicaltrials.gov/study/NCT06668103"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["abbisko"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06668103","phase":"2","setting":"A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of ABSK043 Combined With Firmonertinib in Patients With EGFR Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer(NSCLC)","sponsor":"Abbisko Therapeutics Co, Ltd","enrolled":54,"outcomes":[]},"route":"/trials/nct06668103/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/"}]}}